Measurement of free light chains with assays based on monoclonal antibodies

Henk Te Velthuis; Mark Drayson; John P Campbell

doi:10.1515/cclm-2015-0963

Measurement of free light chains with assays based on monoclonal antibodies

Henk Te Velthuis, Mark Drayson, John P Campbell

Immunology and Immunotherapy

Research output: Contribution to journal › Article › peer-review

17 Citations (Scopus)

561 Downloads (Pure)

Abstract

Recently, serum free light chain (FLC) assays incorporating anti-kappa (κ) and anti-lambda (λ) FLC monoclonal antibodies have become available: N Latex FLC assay (Siemens) and Seralite® (Abingdon Health). The purpose of this review is to provide an overview of these two new monoclonal antibody-based methods. In doing so, the review will outline the performance characteristics of each method, including a summary of: assay principles, antibody specificity, analytical performance and assay performance in disease. Additionally, the review will describe the potential user benefits of adopting these new generation FLC assays, which are designed to overcome the established limitations of existing polyclonal antibody based FLC assays.

Original language	English
Journal	Clinical Chemistry and Laboratory Medicine
DOIs	https://doi.org/10.1515/cclm-2015-0963
Publication status	Published - 24 Mar 2016

Access to Document

10.1515/cclm-2015-0963Licence: None: All rights reserved

cclm-2015-0963
Checked for eligibility: 08/04/2016
Accepted author manuscript, 1.51 MBLicence: None: All rights reserved

Cite this

@article{fe21863e890f40349dab5509391faddf,

title = "Measurement of free light chains with assays based on monoclonal antibodies",

abstract = "Recently, serum free light chain (FLC) assays incorporating anti-kappa (κ) and anti-lambda (λ) FLC monoclonal antibodies have become available: N Latex FLC assay (Siemens) and Seralite{\textregistered} (Abingdon Health). The purpose of this review is to provide an overview of these two new monoclonal antibody-based methods. In doing so, the review will outline the performance characteristics of each method, including a summary of: assay principles, antibody specificity, analytical performance and assay performance in disease. Additionally, the review will describe the potential user benefits of adopting these new generation FLC assays, which are designed to overcome the established limitations of existing polyclonal antibody based FLC assays.",

author = "{Te Velthuis}, Henk and Mark Drayson and Campbell, {John P}",

year = "2016",

month = mar,

day = "24",

doi = "10.1515/cclm-2015-0963",

language = "English",

journal = "Clinical Chemistry and Laboratory Medicine",

issn = "1434-6621",

publisher = "De Gruyter",

}

TY - JOUR

T1 - Measurement of free light chains with assays based on monoclonal antibodies

AU - Te Velthuis, Henk

AU - Drayson, Mark

AU - Campbell, John P

PY - 2016/3/24

Y1 - 2016/3/24

N2 - Recently, serum free light chain (FLC) assays incorporating anti-kappa (κ) and anti-lambda (λ) FLC monoclonal antibodies have become available: N Latex FLC assay (Siemens) and Seralite® (Abingdon Health). The purpose of this review is to provide an overview of these two new monoclonal antibody-based methods. In doing so, the review will outline the performance characteristics of each method, including a summary of: assay principles, antibody specificity, analytical performance and assay performance in disease. Additionally, the review will describe the potential user benefits of adopting these new generation FLC assays, which are designed to overcome the established limitations of existing polyclonal antibody based FLC assays.

AB - Recently, serum free light chain (FLC) assays incorporating anti-kappa (κ) and anti-lambda (λ) FLC monoclonal antibodies have become available: N Latex FLC assay (Siemens) and Seralite® (Abingdon Health). The purpose of this review is to provide an overview of these two new monoclonal antibody-based methods. In doing so, the review will outline the performance characteristics of each method, including a summary of: assay principles, antibody specificity, analytical performance and assay performance in disease. Additionally, the review will describe the potential user benefits of adopting these new generation FLC assays, which are designed to overcome the established limitations of existing polyclonal antibody based FLC assays.

U2 - 10.1515/cclm-2015-0963

DO - 10.1515/cclm-2015-0963

M3 - Article

C2 - 27010775

SN - 1434-6621

JO - Clinical Chemistry and Laboratory Medicine

JF - Clinical Chemistry and Laboratory Medicine

ER -

Measurement of free light chains with assays based on monoclonal antibodies

Abstract

Access to Document

Fingerprint

Cite this